Prelude Therapeutics Stock Market Value
| PRLD Stock | USD 1.97 0.15 7.08% |
| Symbol | Prelude |
Will Biotechnology sector continue expanding? Could Prelude diversify its offerings? Factors like these will boost the valuation of Prelude Therapeutics. Anticipated expansion of Prelude directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Prelude Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Prelude Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Prelude Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Prelude Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Prelude Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prelude Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prelude Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Prelude Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Prelude Therapeutics or generate 0.0% return on investment in Prelude Therapeutics over 90 days. Prelude Therapeutics is related to or competes with Pyxis Oncology, Orchestra BioMed, Enanta Pharmaceuticals, Caribou Biosciences, Inventiva, Tenaya Therapeutics, and Avalo Therapeutics. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development... More
Prelude Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prelude Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prelude Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 13.9 | |||
| Information Ratio | 0.0915 | |||
| Maximum Drawdown | 206.09 | |||
| Value At Risk | (16.17) | |||
| Potential Upside | 16.44 |
Prelude Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prelude Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prelude Therapeutics' standard deviation. In reality, there are many statistical measures that can use Prelude Therapeutics historical prices to predict the future Prelude Therapeutics' volatility.| Risk Adjusted Performance | 0.0795 | |||
| Jensen Alpha | 2.15 | |||
| Total Risk Alpha | 0.134 | |||
| Sortino Ratio | 0.1415 | |||
| Treynor Ratio | (1.13) |
Prelude Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0795 | |||
| Market Risk Adjusted Performance | (1.12) | |||
| Mean Deviation | 9.37 | |||
| Semi Deviation | 11.64 | |||
| Downside Deviation | 13.9 | |||
| Coefficient Of Variation | 1053.22 | |||
| Standard Deviation | 21.49 | |||
| Variance | 461.92 | |||
| Information Ratio | 0.0915 | |||
| Jensen Alpha | 2.15 | |||
| Total Risk Alpha | 0.134 | |||
| Sortino Ratio | 0.1415 | |||
| Treynor Ratio | (1.13) | |||
| Maximum Drawdown | 206.09 | |||
| Value At Risk | (16.17) | |||
| Potential Upside | 16.44 | |||
| Downside Variance | 193.09 | |||
| Semi Variance | 135.52 | |||
| Expected Short fall | (10.42) | |||
| Skewness | 4.86 | |||
| Kurtosis | 36.05 |
Prelude Therapeutics Backtested Returns
Prelude Therapeutics is out of control given 3 months investment horizon. Prelude Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.094, which implies the firm had a 0.094 % return per unit of risk over the last 3 months. We were able to break down and interpolate twenty-seven different technical indicators, which can help you to evaluate if expected returns of 2.1% are justified by taking the suggested risk. Use Prelude Therapeutics Risk Adjusted Performance of 0.0795, semi deviation of 11.64, and Coefficient Of Variation of 1053.22 to evaluate company specific risk that cannot be diversified away. Prelude Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company holds a Beta of -1.8, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Prelude Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Prelude Therapeutics is expected to outperform it. Use Prelude Therapeutics jensen alpha, semi variance, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to analyze future returns on Prelude Therapeutics.
Auto-correlation | -0.13 |
Insignificant reverse predictability
Prelude Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Prelude Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prelude Therapeutics price movement. The serial correlation of -0.13 indicates that less than 13.0% of current Prelude Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.13 | |
| Spearman Rank Test | -0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out Prelude Therapeutics Correlation, Prelude Therapeutics Volatility and Prelude Therapeutics Alpha and Beta module to complement your research on Prelude Therapeutics. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Prelude Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.